TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07288112: DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Sponsor: Diakonos Oncology Corporation · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 35 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,492,260

Rescue Site Savings

+$981,750

Unlock Full NCT07288112 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07288112 Rescue Dossier →